Uveal Melanoma Treatment Market

Uveal Melanoma Treatment Market Outlook (2024 to 2034)

The global uveal melanoma treatment market is analyzed to reach a valuation of US$ 1.59 billion in 2024 and thereafter projected to expand at 7.3% CAGR to touch a value of US$ 3.22 billion by the end of 2034.

Uveal melanoma is a rare cancer, although it is becoming more common globally, especially in areas where UV radiation exposure is higher. This is increasing the need for more potent forms of treatment. In addition, uveal melanoma is detected sooner due to advancements in diagnostic instruments, such as optical coherence tomography (OCT), ultrasound biomicroscopy, and improved imaging techniques. The need for strong therapeutic actions rises with early diagnosis, enhancing treatment outcomes.

Patients with uveal melanoma now have new hope due to the advent of advanced therapies, including immune checkpoint inhibitors and targeted biologics, particularly in cases where cancer has spread. These latest medicines are contributing to the market expansion and increasing demand for therapeutic alternatives.

North America is estimated to account for 36.3% of the global uveal melanoma treatment market share in 2024. The region is leading in the market due to its developed healthcare system, significant healthcare spending, and advanced diagnostic tools. The region is leading when it comes to implementing advanced remedies, such as immunotherapy and targeted therapies.

Clinical trials and ongoing research also contribute to market expansion. The market in East Asia is evaluated to expand at 7.9% CAGR through 2034. This is because the region is becoming a growing market for the treatment of uveal melanoma, as countries, including China, South Korea, and Japan are putting more emphasis on developing their medical infrastructure and cancer treatment programs.

Based on the therapy type, the surgical resection techniques (transretinal endoresection and trans-scleral partial choroidectomy) segment hold 42.3% of the revenue share in 2024. Transretinal Endoresection and Trans-Scleral Partial Choroidectomy are two surgical resection techniques that are in high demand because they provide precise and efficient means of excising uveal melanoma tumors. When a tumor is circumscribed and is removed without requiring enucleation, or the removal of the eye, these surgical approaches are especially helpful in protecting the patient's eyesight.

Report Attributes	Details
Uveal Melanoma Treatment Market Size (2024E)	US$ 1.59 Billion
Forecasted Market Value (2034F)	US$ 3.22 Billion
Global Market Growth Rate (2024 to 2034)	7.3% CAGR
North America Market Share (2024E)	36.3%
Western Europe Market Value (2024E)	US$ 347.04 Million
South Asia & Pacific Market Growth Rate (2024 to 2034)	9.1% CAGR
High-Resolution Ultrasound Biomicroscopy Segment Value (2034F)	US$ 1.2 Billion
Ciliary Melanoma Segment Value (2034F)	US$ 1.62 Billion
Key Companies Profiled	Eli Lilly & Co.; Spectrum Pharmaceuticals Inc.; Novartis AG; Bayer; Astra Zeneca plc; Merck; Amgen; Pfizer Inc.; Roche; Bristol-Myers Squibb Company; Hoffmann-LA

Uveal is found in the back of the sclera and the cornea and has three parts: the iris, the ciliary body, and the choroid. Uveal melanoma, including the iris choroid and ciliary body, is referred to as cancer of the areas of the skin. This is the state in which the tumors emerge from the melanocytes that are responsible for the color of the eye inside the uva.

It is the most common form of intraocular malignancy in adults, although it is an uncommon disorder. The treatment of uveal melanoma depends on the size of the tumor, which is the most significant factor. In the early stages, this kind of melanoma is completely asymptomatic. Some modifications are observed in tumor enlargement over time, such as pupil distortion, reduced visibility due to blurred vision, and secondary retinal detachment.

Fair hair, green or light, and blue colored eyes, and older age are risk variables for this form of cancer. The role of genetic mutations inherited in uveal melanoma is not yet understood. According to the American Cancer Society, the choroid produces about nine out of 10 eye melanomas. According to the American Cancer Society, by the end of 2021, the eye cancer cases including new eye and orbit cancers (primarily melanomas) in the U.S. will reach 3,320, out of which 1,750 in men and 1,570 in women.

What are the Key Trends Impacting the Growth of the Uveal Melanoma Treatment Market?

The global market for uveal melanoma treatment is mainly driven by an increase in the incidence of cases of eye cancer. One of the important reasons for the increase is said to be the rise in the use of electronic devices. This is due to harmful UV radiation that directly affects the eyes of users of smartphones, tablets, desktops, laptops, and other electronic devices. For instance,

• According to the American Cancer Society, adults aged 60 years and above spend 5 or more hours per day using digital devices and prefer laptops & desktops for internet browsing. Thus, this in turn is expected to increase the growth of the uveal melanoma treatment market.

People with a weak immune system are vulnerable to the development of eye cancer. This is due to, a greater risk of primary intraocular lymphoma, such as those with acquired immunodeficiency syndrome (AIDS), those on anti-rejection medications following organ transplantation, or the elderly. Often, infection with a bacterium called Chlamydophila psittaci increases the risk of uveal melanoma.

The bacteria are caught from domestic animals including cats and birds that are infected. Besides, lung infections and conjunctival inflammation or conjunctivitis are caused by these bacteria. Governments of various countries, however, are taking major initiatives to provide better treatment at a minimal cost. Thus, this is in turn supporting the growth of the uveal melanoma treatment market.

How Discovery of Novel Biomarkers Fueling Demand for Uveal Melanoma Treatment?

Increased awareness and growing use of unique biomarkers including blood biomarkers in the diagnosis and treatment of uveal melanoma improves the detection accuracy and time spent on the process, which in turn fuels the revenue opportunities of the uveal melanoma market. Besides, technological developments in the field of biotechnology have improved the identification of possible biomarkers of uveal melanoma.

Some of the new biomarkers adopted for the diagnosis and progression of uveal melanoma include genetic, histological, radiographic, and physiological diagnoses, which are expected to fuel the growth of the Uveal melanoma treatment market.

What are The Key Challenges That Restrain the Growth of the Uveal Melanoma Treatment Market?

There are different factors hindering the growth of uveal melanoma treatment markets, such as the need for adequate skills and experience to conduct uveal melanoma treatment surgeries to provide high-quality and effective treatment services for uveal melanoma.

However, it is expected that a lack of awareness about early signs of eye cancer will deter the development of the global uveal melanoma market. In the early stages of treatment, which are critical for the patient, this causes delay. In addition, costly treatment for eye cancer is pulling down the development of the industry because it is not affordable for patients in underprivileged and underdeveloped areas of the world, which is anticipated to increase the growth of the uveal melanoma treatment market.

Competitive Landscape

Key players such as

• Eli Lilly & Co.
• Spectrum Pharmaceuticals Inc.
• Novartis AG
• Bayer
• Astra Zeneca plc
• Merck
• Amgen
• Pfizer Inc.
• Roche
• Bristol-Myers Squibb Company
• Hoffmann-LA
• Others are actively involved in offering surgery products for uveal melanoma treatment.

What Strategies Are the Key Players Adopting for Increasing Their Market Share in The Uveal Melanoma Treatment Market?

Many companies in the market for uveal melanoma treatment are working to broaden their range of products. The most important approach to raising the customer pool, however, is through the marketing of the product through online portals. It is also expected that making the product available on online platforms would boost uveal melanoma treatment market growth.

In addition, mergers & acquisitions in the market for uveal melanoma care have evolved rapidly over the past few years to increase & improve geographic footprint and achieve operational skills. In the treatment market for uveal melanoma, industry mergers & acquisitions have witnessed steady growth across both expected and profitable customers.

• Immunocore Limited and Eli Lilly and Company announced on June 29, 2015, that they have entered into an immunotherapy-based clinical trial partnership to examine the usefulness for the treatment of melanoma of Immunocore's lead T cell receptor-based research therapeutic, IMCgp100, in combination with Lilly's galunisertib (LY2157299) and merestinib (LY2801653).
• The partnership aims to identify combination regimens in patients with metastatic cutaneous and uveal melanomas that include synergies in efficacy and durability.

What Are the Key Opportunities for Uveal Melanoma Treatment Manufacturers?

The development of an efficient screening tool for uveal melanoma will play a significant role in early detection and subsequent mortality reduction. Over the past few decades, recognition and screening for uveal melanoma have improved, leading to the early detection of uveal melanoma. The ultimate aim of reducing the rate of late-stage illness and mortality has not been achieved, however.

This is primarily due to inadequate screening techniques, which also yield false-positive and false-negative findings. To meet these criteria, groundbreaking companion diagnostic tests will lead to rapid acceptance among doctors and patient populations. Growing demand for safe non-invasive screening methods is therefore expected to fuel the growth of the uveal melanoma treatment market.

Why is the United States A Prominent Market for Uveal Melanoma Treatment?

One of the major reasons is the availability of advanced healthcare services and facilities, that promote early detection of uveal melanoma and multiple palliative therapies. Due to this, the United States holds a significant market share of the uveal melanoma treatment market.

Along with that, the growth of the uveal melanoma treatment market is expected to increase due to awareness of clinical trials to get a closer look at new procedures and treatments and to increase government funding for global disease eradication. Hence, is expected to boost the demand for uveal melanoma treatment.

Will Increasing Geriatric Population Results in Elevation of Uveal Melanoma Treatment Market in India?

Aging is one of the main factors that is impacting the eyecare industry worldwide. The population aged 65+ years is growing day by day and with this growth, the demand for need for eye care-related solutions increases. This increase in population and need represents the market opportunities for new consumers in India.

The market in India is expected to grow at a lucrative rate owing to the constant rise in the incidence of eye cancer coupled with increased demand for cost-efficient therapeutics. Besides, owing to the presence of a large number of clinical research organizations, several pharmaceutical firms are drawn to this region for the production of effective and cheaper therapy. Thus, this in turn is expected to boost the demand for uveal melanoma Treatment.

According to WHO, by 2050, low-middle-income countries will comprise almost 80% of all older people.

• According to the UN Economic and Social Affairs Report (2019), the population of people aged over 65 years in Asia is expected to increase from 395.3 million in 2019 to 587.4 million by 2030, which will consequently drive the prevalence of age-related eye diseases in the region. The prevalence of glaucoma in adults over 45 years of age in China is about 3.5 percent; however, it rises dramatically with age, and in the population over 65 years of age it is estimated to be about 9 percent.
• People with uveal melanoma are at risk of blindness or significant vision loss if left untreated. Most of the vision loss or related problems are preventable or treatable through simple measures.

The research report on the uveal melanoma treatment market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on the uveal melanoma treatment market provides analysis and information according to market segments such as geographies, diagnostic tests, therapy type, location type, eye exam, end user, and industry.

The Report Covers Exhaust Analysis On Uveal Melanoma Treatment market

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Report On Uveal Melanoma Treatment Market Includes Regional Analysis

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Europe (Germany, Italy, France, UK, Spain, Russia)
• East Asia (China, Japan, South Korea)
• South Asia (India, ASEAN)
• Oceania (Australia, New Zealand)
• Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report on the uveal melanoma treatment market is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report on Uveal Melanoma Treatment Market Highlights

• Detailed overview of the parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Segmentation of Uveal Melanoma Treatment Market Research

• By Diagnostic Test :

  • High-Resolution Ultrasound Biomicroscopy
  • Fluorescein Angiography
  • Ultrasonography
  • Ocular Coherence Tomography
  • Indocyanine Green Angiography

• By Therapy Type :

  • Surgical Resection Techniques
  • Transpupillary Thermotherapy
  • Radiation Therapies
  • External Beam Proton Therapy
  • Gamma Knife Stereotactic Surgery

• By Location Type :

  • Ciliary Melanoma
  • Iris Melanoma
  • Choroid Melanoma

• By Eye Exam :

  • Gonioscopy
  • Ophthalmoscopy
  • Slit-Lamp Biomicroscopy

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa